New TaqMan® Mutation Detection Assays with innovative castPCR™ technology were specifically developed to detect somatic mutations in key cancer genes. By combining the power of the 2 technologies, TaqMan® and castPCR™, these new assays give you:

  • Higher specificity—designed to block the wild-type and amplify only the mutant
  • Higher sensitivity—designed to detect somatic mutations down to 1 cancer cell in 1,000 normal cells
  • Faster workflow—3 hours from sample to result

With 778 assays for 46 cancer genes available today like KRAS, BRAF, KIT, JAK2, the TaqMan® Mutation Detection Assays provide an innovative tool for your cancer research.
Not seeing what you're looking for? We have custom solutions >

Your Innovative Research Using TaqMan® Mutation Detection Assays

Learn how other researchers use the TaqMan® Mutation Detection Assays.

Q-PCR and sequence analysis of DNA template from a microfluidic CTC isolation platform.
Poster presented at AACR 2012 by Cynvenio Biosystems, Inc.

University Hospitals Coventry and Warwickshire: KRAS mutation analysis by PCR: a comparison of two methods.
Poster presented at EACR 2012 by Dr Ian A.Cree

K-RAS mutation detection in colorectal cancer-A combined approach using TaqMan® Mutation Detection Assays (TMDA) and digital PCR.
Poster presented at EACR 2012 by Dr Orla Sheils *

For Research Use Only. Not for use in diagnostic procedures.
*This application has not been tested by Life Technologies and Life Technologies cannot guarantee its accuracy. However, at least one customer or third party has successfully performed this application. Life Technologies does not endorse the information provided herein and is providing this application for informational purposes only.